The biology and treatment of acute progranulocytic leukemia

Current Opinion in Oncology

Volumn 11, Issue 1, 1999, Pages 9-13

  Slack, James L ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ARSENIC TRIOXIDE; CYTARABINE; DAUNORUBICIN; ENZYME INHIBITOR; HISTONE DEACETYLASE; IDARUBICIN; REPRESSOR PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; GENE FUSION; GENE REPRESSION; GENE TARGETING; HUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN DNA BINDING; RETINOIC ACID SYNDROME; REVIEW; TRANSCRIPTION REGULATION;

CELL TRANSFORMATION, NEOPLASTIC; DNA-BINDING PROTEINS; HISTONE DEACETYLASES; HUMANS; INTERLEUKIN-6; LEUKEMIA, PROMYELOCYTIC, ACUTE; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; ONCOGENES; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, RETINOIC ACID; TRANSCRIPTION FACTORS; TRETINOIN;

EID: 0033003054     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199901000-00003     Document Type: Review

References (25)

1. 1 Bonnet D, Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3:730-737.
2. 2 Ferrucci PF, Grignani F, Pearson M, Fagioli M, Nicoletti I, Pelicci PG: Cell death induction by the acute promyelocytic leukemia-specific PML/RARα fusion protein. Proc Natl Acad Sci U S A 1997, 94:10901-10906. Among hematopoietic cell lines tested, only KG-1a, U937, K562, and TF-1 were permissive for PML-RARα expression. PML-RARα caused growth inhibition and apoptosis of fibroblasts. Its cell death function required not only the PML aminoterminal region, but also the RARα DNA binding domain.
3. 3 Barr FG: Translocations, cancer, and the puzzle of specificity. Nat Genet 1998, 19:121-124.
4. 4 Fagioli M, Alcalay M, Tomassoni L, Ferrucci PF, Mencarelli A, Riganelli D, et al.: Cooperation between the RING + B1-B2 and coiled-coil domains of PML is necessary for its effects on cell survival. Oncogene 1998, 16:2905-2913.
5. 5 Wang ZG, Delva L, Gaboli M, Rivi R, Giorgio M, Cordon-Cardo C, et al.: Role of PML in cell growth and the retinoic acid pathway. Science 1998, 279:1547-1551. This article provides a plausible explanation of why PML is the RARα translocation partner in more than 99% of cases of APL and suggests that disruption of PML function is involved in the differentiation block found in APL.
6. 6 Pazin MJ, Kadonaga JT: What's up and down with histone deacetylation and transcription. Cell 1997, 89:325-328.
7. 7 Sobulo OM, Borrow J, Tomek R, Reshmi S, Harden A, Schlegelberger B, et al.: MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3). Proc Natl Acad Sci U S A 1997, 94:8732-8737.
8. 8 Carapeti M, Aguiar RC, Goldman JM, Cross NC: A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia. Blood 1998, 91:3127-3133.
9. 9 Hong SH, David G, Wong CW, Dejean A, Privalsky ML: SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor α (RARα) and PLZF-RARα oncoproteins associated with acute promyelocytic leukemia. Proc Natl Acad Sci U S A 1997, 94:9028-9033. This was the first report to show that RARα fusion proteins involved in APL mimic wild-type RARα in their ability to associate with the SMRT corepressor. It was also shown that PLZF independently associated with SMRT via the POZ domain and that this interaction was insensitive to retinoic acid.
10. 10 Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, et al.: Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia. Nature 1998, 391:815-818. This is one of a series of four papers (see references 11••-13••), all published in spring 1998, that established a connection between the fusion proteins involved in APL, nuclear corepressors, and histone deacetylase activity. All four papers suggest that the reason patients with APL caused by PLZF-RARα are not sensitive to RA is due to a hormone-insensitive corepressor binding site in PLZF (but not PML). In this paper, mutation of the CoR binding site in PML-RARα blocked the ability of PML-RARα to inhibit differentiation in vitro.
11. 11 Lin RJ, Nagy L, Inoue S, Shao W, Miller WH Jr, Evans RM: Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 1998, 391:811-814. This paper showed that RA could not release SMRT from a mutant form of PML-RARα that was deficient in ligand binding. Because similar mutant forms of PML-RARα have been found clinically, this finding may have relevance for the development of RA resistance in patients.
12. 12 Guidez F, Ivins S, Zhu J, Soderstrom M, Waxman S, Zelent A: Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML-and PLZF-RARα underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood 1998, 91:2634-2642. This paper showed that histone deacetylase inhibitors relieved the transcriptional inhibitory activity of PML-RARα and PLZF-RARα on RARE targets.
13. 13 He LZ, Guidez F, Tribioli C, Peruzzi D, Ruthardt M, Zelent A, Pandolfi PP: Distinct interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to RA in APL. Nat Genet 1998, 18:126-135. Transgenic mice expressing either PML-RARα or PLZF-RARα were compared. Most notably, all of the PLZF-RARα transgenic mice died of leukemia between 6 months and 1.5 years (compared with 25% of PML-RARα positive mice). The leukemia in PLZF-RARα transgenics was more similar to chronic myeloid leukemia than to APL. Similar to human PLZF-RARα APL, RA at conventional doses had little effect on mice with PLZF-RARα-induced leukemia; however, at high doses, RA could induce clinical remission. Finally, combination treatment of PLZF-RARα leukemic cells with RA and the histone deacetylase inhibitor trichostatin A resulted in the induction of differentiation of these cells, establishing a role for histone deacetylase activity and transcriptional repression in APL pathogenesis.
14. 14 Dhordain P, Albagli O, Lin RJ, Ansieau S, Quief S, Leutz A, et al.: Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein. Proc Natl Acad Sci U S A 1997, 94:10762-10767.
15. 15 David G, Alland L, Hong SH, Wong CW, DePinho RA, Dejean A: Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein. Oncogene 1998, 16:2549-2556.
16. 16 Culligan DJ, Stevenson D, Chee YL, Grimwade D: Acute promyelocytic leukaemia with t(11;17)(q23;q12-21) and a good initial response to prolonged ATRA and combination chemotherapy. Br J Haematol 1998, 100:328-330.
17. 17 Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C, et al.: Molecular remission in PML/RARα-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood 1997, 90:1014-1021. This study showed a remarkable 95% CR rate with the AIDA protocol. No patient had resistant APL.
18. 18 Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JE, Ogden A, et al.: All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997, 337:1021-1028. This definitive, large, randomized trial proved the superiority of RA over standard chemotherapy for induction therapy of APL.
19. 19 Asou N, Adachi K, Tamura J, Kanamaru A, Kageyama S, Hiraoka A, et al.: Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol 1998, 16:78-85.
20. 20 Gallagher RE, Willman CL, Slack JL, Andersen J, Li Y, Viswanatha D, et al.: Association of PML-RARα fusion mRNA type with pre-treatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study. Blood 1997, 90:1656-1663. The PML-RARα S isoform was associated with a higher leukocyte count, but isoform type per se (L versus S) was not an independent prognostic factor for disease-free or overall survival.
21. 4 may be useful in serial monitoring but requires frequent bone marrow samples and misses approximately 30% of relapses. At this sensitivity level, almost all patients (96%) have RT-PCR-negative results after consolidation.
22. 22 Gianni M, Koken MH, Chelbi-Alix MK, Benoit G, Lanotte M, Chen Z, de The H: Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood 1998, 91:4300-4310.
23. 23 Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K, et al.: Arsenic trioxide as an inducer of apoptosis and loss of PML/RARα protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 1998, 90:124-133.
24. 24 Meloni G, Diverio D, Vignetti M, Avvisati G, Capria S, Petti MC, et al.: Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RARα fusion gene. Blood 1997, 90:1321-1325.
25. 25 Wells RA, Catzavelos C, Kamel-Reid S: Fusion of retinoic acid receptor α to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukemia. Nat Genet 1997, 17:109-113.